6 completed, 4 terminated, 2 withdrawn, 1 recruiting. 5 Phase 2, 5 Phase 3, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Recruiting 1, Terminated 1 |
| Phase 3 | 5 | Completed 4, Terminated 1 |
| Phase 1 | 4 | Terminated 2, Withdrawn 2 |
Follow GW Pharmaceuticals Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS) CBDV Compound, Placebo - Prader-Willi Syndrome | Phase 2 | Terminated | Eric Hollander | 6 | 2020-11-23 | 2026-05-07 |
| Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm Cannabidiol Oral Solution [Epidiolex] - Blepharospasm, Blepharospasm, Benign Essential | Phase 2 / Phase 3 | Completed | Silkiss Eye Surgery | 12 | 2020-05-20 | 2021-11-02 |
| A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome GWP42003-P - Rett Syndrome, RTT | Phase 3 | Terminated | Jazz Pharmaceuticals | 21 | 2020-02-28 | 2022-08-08 |
| Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) Cannabidivarin, Matched Placebo - Autism Spectrum Disorder | Phase 2 | Recruiting | Montefiore Medical Center | 100 | 2019-04-12 | 2025-10-22 |
| An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) GWP42003-P - Tuberous Sclerosis Complex, Seizures | Phase 3 | Completed | Jazz Pharmaceuticals | 199 | 2016-08-31 | 2022-07-14 |
| A Study to Evaluate the Pharmacokinetics Of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease, Compared to Matched Subjects With Normal Renal Function. Sativex - Renal Insufficiency, Kidney Disease | Phase 1 | Withdrawn | GW Pharmaceuticals Ltd | 2016-01-01 | 2016-08-11 | |
| A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer Sativex - Advanced Cancer | Phase 1 | Withdrawn | GW Pharmaceuticals Ltd | 2015-10-01 | 2016-03-02 | |
| A Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex® in a Range of Oral pH Environments in Healthy Subjects Sativex - Healthy Volunteers | Phase 1 | Terminated | GW Pharmaceuticals Ltd | 6 | 2014-08-01 | 2021-02-05 |
| A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis Sativex - Head and Neck Squamous Cell Carcinoma | Phase 1 | Terminated | GW Pharmaceuticals Ltd | 10 | 2014-02-01 | 2016-08-11 |
| Neuroprotection by Cannabinoids in Huntington's Disease delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), Placebo - Huntington's Disease | Phase 2 | Completed | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | 25 | 2011-09-01 | 2013-02-01 |
| Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer Nabiximols, Placebo (GA-0034) - Pain, Advanced Cancer | Phase 3 | Completed | GW Pharmaceuticals Ltd | 397 | 2010-11-25 | 2018-04-23 |
| A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. Sativex Low Dose, Sativex Medium Dose, Sativex High Dose - Palliative Care, Pain | Phase 2 | Completed | GW Pharmaceuticals Ltd | 360 | 2007-11-01 | 2013-06-20 |
| Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS Sativex, Placebo - Multiple Sclerosis | Phase 3 | Completed | GW Pharmaceuticals Ltd | 339 | 2006-09-01 | 2013-06-24 |
Marijuana Abuse (2) · Pain (2) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · Benign essential blepharospasm (1) · Blepharospasm (1) · Cancer Pain (1) · Huntington Disease (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Multiple Sclerosis (1) · Neoplasms (1) · Prader-Willi Syndrome (1) · Renal Insufficiency (1) · Rett Syndrome (1)
nabiximols (7) · Cannabidiol (4) · cannabidivarin (2) · Dronabinol (1)
United States (7) · United Kingdom (4) · Canada (3) · Spain (3) · Belgium (2) · Czechia (2) · Germany (2) · Italy (2) · Poland (2) · Romania (2) · Australia (1) · Bulgaria (1) · Chile (1) · Finland (1) · France (1)
Eric Hollander, MD (2) · Gerard S Barron, BSc (1) · James Ritter, DPhil FRCP FMedSci (1) · James Ritter, DPhil, FRCP, FMedSci (1)
PMID 22483680, PMID 23180178, PMID 27159993, PMID 34957550, PMID 37606606, PMID 40656115
2009 (1), 2014 (1), 2015 (1), 2019 (1)